Carteyva CAR-T Achieves Durable Complete Remission in High-Risk POD24 Follicular Lymphoma
27/07/2026
A patient with high-risk POD24 follicular lymphoma achieved durable complete remission after treatment with Carteuva CD19 CAR-T therapy. This case highlights the growing role of CAR-T therapy in patients with early relapse and limited treatment options.